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Ascites and renal dysfunction in cirrhosis occur when the liver disease is decompensated and signify the presence of advanced
liver failure. However, the precipitating causes should be looked for and treated. Although liver transplantation is the treatment
of choice in patients with advanced liver failure, mild to moderate ascites can be treated eﬀectively with medical management.
Similarly, renal failure in cirrhotics is reversible if the precipitating causes can be treated eﬀectively and by use of combination of
vasoconstrictors and albumin. Transjugular intrahepatic portosystemic shunts also oﬀer an eﬀective therapy for refractory ascites
and HRS. Such treatments may oﬀer eﬀective bridge to liver transplantation, by improving short and medium term survivals.
Here, we shall discuss all the options available for the management of these complications of cirrhosis.
1.Introduction
Ascites is one of the indicators of decompensation and poor
prognosis in patients with cirrhosis of any etiology. Once
ascites develops, the predicted mortality is approximately
50% at 2 years [1]. Ascites is also an indicator of advanced
portal hypertension. In many natural history series of
cirrhosis, ascites is the most frequent ﬁrst complication of
cirrhosis preceded only by hepatocellular carcinoma [2]. In
addition to being a poor prognostic factor, it also leads to
signiﬁcant morbidity in cirrhotics. But it is important to
remember that patients with cirrhosis are not immune to
develop ascites due to other causes, such as tuberculosis,
malignancy, intrinsic renal disease, or heart failure. For this
reason,itisimportanttocarryoutacompleteevaluationand
treat it appropriately.
2.DiagnosisofAscites
When a cirrhotic presents for the ﬁrst time with abdominal
distension then, unless proved otherwise, the ascites is
secondary to portal hypertension. A reasonable estimate
can be made from a detailed history, examination, and
biochemical assessment.
2.1. Ascitic Fluid Analysis. A detailed laboratory assessment
of the ascitic ﬂuid is a must in all patients who present with
ascites for the ﬁrsttime. It conﬁrms the diagnosis of cirrhotic
ascites, rules out other causes of ascites, and also detects
presence of spontaneous bacterial peritonitis. Measurement
of serum to ascitic ﬂuid albumin gradient (SAAG) readily
diﬀerentiates ascites due to portal hypertension and ascites
due to other causes. Almost simultaneous measurement
of ascitic ﬂuid and serum albumin is required. SAAG of
≥1.1 suggests the presence of portal hypertension with an
accuracy of 97% [3]. The importance of measuring total
ascitic ﬂuid protein is to assess the risk of developing
spontaneous bacterial peritonitis (SBP) later and therefore
recommending antibiotics for primary prophylaxis of SBP.
Cirrhotics who have total ascitic ﬂuid protein concentration
less than 1.5gm/dL are at an increased risk of developing
SBP [4]. Measurement of total and diﬀerential cell count is
essential at both the initial evaluation and all subsequent
times when ascitic ﬂuid is drained, in order to look for2 International Journal of Hepatology
evidenceofSBP.SBPisdiagnosedwhentheneutrophilcount
of the ascitic ﬂuid is more than 250/cumm. The prevalence
of SBP in cirrhotic patients attending the outpatient clinics is
1.5–3.5%[5].Atthesametimeasciticﬂuidshouldbesentfor
culture by inoculating in the blood culture bottles bed side.
This technique can yield a positive culture in about 40% of
the cases.
Patients who have high ascitic ﬂuid protein content
along with lymphocyte predominant ascites usually have
other inﬂammatory or malignant causes for ascites, such as
peritoneal tuberculosis [6] or peritoneal metastatic deposits.
Adenosine deaminase enzyme which is released from lym-
phocytes has been shown to be raised in patients with
peritoneal tuberculosis. In a meta-analysis of 4 studies which
included 264 patients, peritoneal ﬂuid ADA had a sensitivity
of 100% and speciﬁcity of 97% for making a diagnosis of
tubercular ascites. The optimal cut-oﬀ value deﬁned was
39IU/L [7]. In another article, the ADA among patients
with tubercular ascites was found to be signiﬁcantly higher
than the values in patients with other causes of ascites (sep-
tic peritonitis, malignant ascites, and transudative ascites)
[8].
3.A scit esandI tsM anag e me nt
Ascites in cirrhotics should be treated because it is associated
with discomfort, reduced respiratory excursion, reduced
appetite because of pressure eﬀect, and predisposition to
SBP. Presence of current ascites also negatively impacts the
quality-of-life scores in cirrhotics and therefore warrants
treatment [9]. For management purposes, ascites has be
classiﬁed into mild or grade 1 (only detectable by ultra-
sonography), moderate or grade 2 (moderate symmetrical
distension of abdomen), and severe or grade 3 (large or tense
ascites), by the international ascites club.
3.1.SaltRestriction. Dietarysaltrestrictionshouldberecom-
mended for all patients who present with ascites for the ﬁrst
time and have grade 1 or 2 ascites. The recommended salt
intake in such patients is between 80–120mmol of sodium
per day, which corresponds to 4.6–6.9gm of salt. A negative
sodium balance can be obtained by reducing dietary salt
intake in 10–20% of cirrhotics with ascites [10].
3.2.Diuretics. Intheinitialmanagementofmildtomoderate
ascites (which is not tense), aldosterone antagonists should
be started ﬁrst, since the pathophysiology of sodium reten-
tion in cirrhotics is due to increased reabsorption of sodium
from the proximal and distal tubule and the mediator
of this reabsorption is secondary hyperaldosteronism [11].
Spironolactone, which is an aldosterone antagonist, should
bestartedﬁrstinadoseof100mg/dayandthedoseincreased
in 100mg increment every 7 days till 400mg. Beyond this,
loop diuretic, furosemide should be added in a dose of
40mg per day and added in increment of 40mg till a total
of 160mg. The dose of diuretics should be adjusted to
achieve a weight reduction of 0.5kg/day in patients without
pedal edema and about 1.0kg/day in patients with pedal
edema. Higher doses of diuretics in patients without pedal
edema can result in complications such as hyponatremia or
azotemia. It has been suggested that for patients with mild
to moderate ascites who present for the ﬁrst time, the above
mentioned regimen should be followed, but for patients
with resistant ascites or recurrent ascites, a combination of
spironolactone and furosemide (100mg and 40mg, resp.)
should be started at the outset [12]. The newer loop diuretic
t o r s e m i d ei sm o r ep o t e n tt h a nf u r o s e m i d ea n dh a sb e e n
shown to be as eﬀective and safe as furosemide in a small
study of 46 cirrhotics with ascites [13].
Diuretics can induce electrolyte imbalances; furosemide
can induce hypokalemia, spironolactone can induce hyper-
kalemia because of its potassium sparing eﬀect, and
both these diuretics can induce hyponatremia. Therefore,
furosemide should be discontinued if serum potassium
is <3mmol/L, and spironolactone should be stopped if
serum potassium is >6mmol/L. If the serum sodium is
<120mmol/L, no diuretic should be given. Diuretics should
also be discontinued if there are other diuretic induced
complications such as renal failure, worsening hepatic
encephalopathy, or severe muscle cramps.
3.3. Large Volume Paracentesis (LVP). LVP, as the name
suggests, is deﬁned as drainage of large volumes (>5-6 litres)
of ascites. It is the treatment of choice for tense ascites (grade
3 ascites). It is more eﬀective and safer than just diuretic
therapy for tense ascites. But diuretics should always be given
after LVP in order to prevent reaccumulation of ascites, since
diureticswouldberequiredtoreversethepathophysiologyof
sodium retention.
However, LVP may be associated with the development
of post-paracentesis circulatory dysfunction (PPCD) which
involves a rise in cardiac output, fall in systemic vascular
resistance, and a rise in serum rennin and aldosterone. These
changes are usually maintained for up to 24 hours, and
the hormonal changes may last up to 6 days [14]. PPCD
can be prevented by concomitant administration of plasma
expanders, and the most eﬀective plasma expander for this
purpose has been demonstrated to be albumin which should
be given in a dose of 8gm/litre of ascitic ﬂuid drained.
Although cheaper alternatives such as dextran-70 have also
been used eﬀectively to prevent PPCD associated with LVP
[15], albumin has been shown to be more eﬀective than
other plasma expanders if volumes of >5 litres are removed.
In this randomized controlled trial, the incidence of PPCD
was 18.5%, 34.4%, and 37.85 in patients receiving albumin,
dextran-70, and polygeline, respectively, and the type of
plasma expander used has been shown to be an independent
predictor of development of PPCD [16, 17].
LVP is also an eﬀective treatment for refractory ascites.
Refractory ascites can be divided into two categories:
diuretic-resistantascites(deﬁnedastheascitesthatcannotbe
mobilized, or early recurrence of which cannot be prevented
due to lack of response to adequate sodium restriction and
diuretic treatment; patients should be taking at least 400mg
of spironolactone and 160mg of furosemide for at least one
week, along with salt restricted diet of <90mmol/L) andInternational Journal of Hepatology 3
diuretic-intractable ascites (deﬁned as the ascites that cannot
be mobilized, or early recurrence of which cannot be pre-
vented because of development of complications of diuretic
dose such as, diuretic-induced hepatic encephalopathy,
renal dysfunction, hyponatremia, hypo- or hyperkalemia)
[18].
3.4. Transjugular Intrahepatic Portosystemic Shunts (TIPS).
Sinceascitesincirrhosisdevelopsduetoportalhypertension,
it would seem logical to decompress the portal system
to reduce the ascites. So TIPS has been tried in several
uncontrolled and controlled trials for refractory ascites.
TIPS is useful and safe in patients with refractory ascites,
where portal hypertension is not associated with presence of
advanced liver failure. The randomized trials which assessed
the role of TIPS versus LVP had excluded patients who
had evidence of advanced liver disease (serum bilirubin >
5mg%, INR > 2, presence of recurrent or persistent hep-
atic encephalopathy, renal failure). These trials consistently
showed better control of ascites with TIPS, but the eﬀect on
survival was inconsistent. The studies that included small
number of patients or included a mix of refractory and
recurrent ascites did show some survival advantage [19–
21], but the studies which included purely refractory ascites
and had signiﬁcant sample sizes did not show any survival
advantage of TIPS over LVP [22, 23]. Meta-analysis includ-
ing these ﬁve trials (>300 patients) again demonstrated
that there was signiﬁcantly better control of ascites (OR
ranging from 0.07–0.56) with a higher incidence of hepatic
encephalopathy (OR ranging from 1.72 to 2.26) in the TIPS
group [24–27], and only one meta-analysis demonstrated an
increase in transplant-free survival in patients undergoing
TIPS (P = 0.035) [28]. TIPS appears to be an eﬀective
therapy for refractory ascites, but it should be emphasized
that the patients should be carefully selected for this pro-
cedure.
3.5. Aquaretics. Since the basic pathophysiology of water
retention and dilutional hyponatremia in cirrhotics is antidi-
uretichormoneorargininevasopressin(AVP)inducedwater
resorption from the distal collecting duct, it would appear
logical to block this action of AVP and inhibit the pure water
resorption. AVP acts at this level through the V2 receptors
on the distal collecting tubule. Recently, a new class of drugs
called vaptans, which act by blocking the V2 receptors have
been shown to improve free water clearance in patients with
a number of conditions associated with water retention, such
as congestive heart failure and cirrhosis.
Initial studies with an orally active V2 receptor blocker,
satavaptan, did show improvement in hyponatremia and
control of ascites in combination with diuretics, but a phase
3 RCT in combination with diuretics failed to demonstrate
a signiﬁcant eﬀect on control of ascites. In addition, there
was an increase in morbidity and mortality in the active
treatment arm [29]. Recently, another V2 receptor blocker,
tolvaptan, has been approved for management of dilutional
hyponatremia in cirrhotics [30] and is expected to help in
reduction of water retention as well in these patients.
3.6.LiverTransplantation. Allpatientswithrefractoryascites
have advanced liver failure and therefore should be oﬀered
liver transplantation, if all other precipitating causes of acute
deterioration have been ruled out. However, many patients
who have ascites may not meet the MELD score cutoﬀs
where transplantation is recommended. MELD score, alone,
probablyunderestimatestheriskofmortalityinpatientswho
have ascites [31].
4.Renal FailureinCirrhosisand
Its Management
Renal dysfunction among cirrhotics is associated with a very
poor prognosis, so it forms a part of the prognostic MELD
score. Acute renal dysfunction or acute kidney injury (AKI)
(abrupt rise in serum creatinine by 0.3mg%) in cirrhotics
can be classiﬁed into prerenal azotemia (volume responsive
prerenalAKI),acutetubularnecrosis(ATN)andhepatorenal
syndrome (HRS) (volume unresponsive prerenal, functional
type AKI). In an Indian tertiary care hospital, the most
common cause of AKI in cirrhotics was found to be acute
tubular necrosis (44.4%), followed by prerenal azotemia
(36.4%), and hepatorenal syndrome (HRS) (19.2%) [32].
However, studies from the west indicate that the most
common form of AKI among cirrhotics is prerenal (volume
responsive)azotemia(66%)followedbyATNandHRSbeing
the least common form [33]. Here, we shall discuss the
management of HRS in cirrhotics since it is the most severe
and prognostically most important form of renal failure in
this group of patients.
Other forms of renal failure can be diﬀerentiated from
HRS, in cirrhotics, by urine routine and microscopic exam-
ination (presence of signiﬁcant proteinuria, casts and/or
hematuriasuggestsintrinsicrenaldisease),ultrasoundexam-
ination of kidney, ureters and bladder (presence of shrunken
kidneys with loss of corticomedullary diﬀerentiation or
presence of obstructive uropathy suggests non-HRS AKI),
response to ﬂuid replacement (improvement in serum
creatinine with volume replacement suggests prerenal AKI),
and by history of recent use of nephrotoxic drugs and active
sepsis (suggest acute tubular necrosis). The principles of
management of non-HRS AKI depend on the cause of AKI.
However, when it is diﬃcult to rule out other causes, it is
important to replace volume as is described below; stop all
nephrotoxic drugs, and treat active sepsis if present. This
would take care of most forms of renal failure. Dialysis may
be requiredforspeciﬁc indications (hyperkalemia,metabolic
acidosis, uremic encephalopathy, and pericarditis).
5. HepatorenalSyndrome
HRS is deﬁned as the development of renal failure in
patients with advanced liver disease in the absence of other
identiﬁable causes of renal failure. Recently, modiﬁed criteria
have been laid down for the diagnosis of hepatorenal syn-
drome (Table 1). So it is important to exclude hypovolemia,
use of nephrotoxic drugs, and presence of intrinsic renal
disease before a diagnosis of HRS can be made. One of4 International Journal of Hepatology
Table 1: Diagnostic criteria for hepatorenal syndrome.
Modiﬁed criteria for diagnosis of hepatorenal syndrome
Cirrhosis with ascites
Serum creatinine > 1.5mg%
Absence of shock
Absence of hypovolemia (no improvement in renal function after
at least 2 days of diuretic withdrawal and volume expansion with
albumin in a dose of 1gm/kg/day)
No ongoing or recent treatment with nephrotoxic drugs
Absenceofintrinsicrenaldisease(proteinuria<0.5gm/day;urine
RBCs < 50/HPF; normal renal ultrasound)
the important changes from the previous deﬁnition of HRS
is the understanding that HRS can also be diagnosed in
the presence of active sepsis, which earlier used to be an
exclusion criteria. HRS can be of two types. Type 1 HRS
develops rapidly with a rise in serum creatinine to >2.5mg%
in less than 2 weeks. It is usually preceded by a precipitating
event, and the most common being some bacterial infection
such as spontaneous bacterial peritonitis. Type 2 HRS is
characterized by a slower development of renal dysfunction
and usually develops in the setting of refractory ascites.
According to another recent, modiﬁed classiﬁcation of renal
failure among cirrhotics, given by a working party, type
1 HRS may be considered as a form of AKI in cirrhotics
and type 2 HRS may be considered as CKD in cirrhotics
[34]. HRS type I has a very poor prognosis in cirrhotics
and predicts a median survival of only 3 months [35],
and untreated type 1 HRS has a median survival of about
1 month.
6. Treatment of HRS (Table 2)
As has been mentioned earlier, hypovolemia needs to be
corrected by stopping all diuretics for at least 48 hours and
by administration of albumin before labelling a patient as
havingHRS.Sepsisshouldbeactivelylookedfor(sincesepsis
is the most common precipitant of HRS), by blood cultures,
urine cultures, ascitic ﬂuid cytology and cultures, and chest
radiographs, and treated with appropriate antibiotics.
6.1. Vasoconstrictors. Vasoconstrictors act by counteracting
the strong splanchnic vasodilatation, which is characteristic
of advanced cirrhosis. The most common drug used for this
purpose is the vasopressin analogue, terlipressin. Terlipressin
is used at a dose of 1mg every 4–6 hrly and increased, if there
is no response (<25% reduction in serum creatinine at day
3), to a maximum of 2 mg every 4–6 hourly”. Treatment
is to be continued till the serum creatinine falls to less
than 1.5mg%. Trial of treatment with terlipressin should
be continued up to 2 weeks. Beyond this, if there is no
response, it should be discontinued. This has to be given
alongwithalbumininadoseof1gm/kgonday1followedby
20–40gm per day. Treatment with terlipressin is associated
with improvement in urine output, reduction in creatinine
levels, reduction in renin levels, and improvement in mean
Table 2: Therapeutic modalities used in HRS and their eﬀect on
renal function and survival.
Therapeutic modality Studies Improved
renal function
Improved
survival
Terlipressin plus
albumin
RCTs and
meta-
analysis
Yes Yes
Noradrenaline plus
Albumin RCTs Yes ? yes
Midodrine plus
octreotide plus albumin
Single small
RCT Yes No
TIPS Non-RCTs Yes No
Albumin dialysis Small RCT Yes No
Liver transplantation Yes Yes
arterial pressure. Eﬀect on survival was demonstrable in
some but not all studies. A systemic review of the use of
vasoconstrictors in patients with type 1 and type 2 HRS
demonstrated that terlipressin plus albumin improved short
term survival (15 days survival) (RR 0.81, 0.68–0.97) in
patients with type 1 HRS, but not in type 2 HRS. There
was no improvement in 30-day, 90-day, or 180-day survival
[36]. Another systematic review, which included 4 RCTs of
terlipressin in type 1 HRS, demonstrated reversal of HRS
and trend towards improved 90 days survival [37]. Use of
terlipressin is associated with ischemic side eﬀects (cardiac,
digital, and mesenteric) in as many as 12% of patients, and
it is usually contraindicated in patients who have coronary
artery disease and peripheral vascular disease.
Noradrenaline infusion (dose ranging from 0.5 to
3mg/hour) along with albumin has also been shown to
be as eﬀective as terlipressin plus albumin in improving
renal function and circulatory function in patients with
HRS [38]. Another larger open lablelled RCT (20 patients
in each arm; noradrenaline plus albumin versus terlipressin
plus albumin), published from India, demonstrated similar
improvement in renal functions and similar survival rates in
the two groups [39].
Alpha-adrenergic agonist, midodrine, is another vaso-
constrictor which has been used in patients with HRS.
Midodrine was used in a dose of 2.5 to 12.5mg orally
every 8 hourly in combination with octreotide 100µg
subcutaneously, 8 hourly in 5 patients with HRS type 1.
These were compared with 8 patients who were managed
with standard therapy. Both groups also received albumin
(50–100mL daily). Patients who received the combination
therapy had reversal of HRS with signiﬁcant increase in
GFR and reduction in plasma renin activity. There were no
ischemic side eﬀects [40].
6.2. Transjugular Intrahepatic Portosystemic Shunts (TIPS) for
HRS. TIPShasbeenusedtocontrolportalhypertensionand
has been found to be useful in patients with HRS as well.
However, many patients with advanced liver disease with
renal failure have contraindications for the use of TIPS. A
single centre study in 129 patients with long-term followup
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after placement of TIPS. Amount of iodinated contrast
medium administered did not aﬀect creatinine levels [41].
Among 41 patients (21 with HRS type 1 and 20 with
HRS type 2), TIPS placement not only improved creatinine
clearance (18 ± 15 to 48 ± 42mL/min) and urinary sodium
excretion (9 ± 16 to 77 ± 78mmol/24 hours), but also gave
a one-year survival of 48% [42]. However, there is no RCT
comparing TIPS with other forms of therapy in patients with
HRS.
6.3. Albumin Dialysis. Albumin dialysis is supposed to act
on the principle of removing albumin bound toxins, which
in case of HRS would be cytokines and vasodilators. In
a small RCT among 13 patients with type 1 HRS, there
was a signiﬁcant improvement in renal function and short-
term mortality (100% at day 7 in the standard medical
therapy group (n = 5) versus 26.5% in the MARS group
(n = 8)) in patients undergoing molecular adsorbent and
recirculatingsystem(MARS)therapy[43].However,arecent
pilot study in 6 patients with HRS who had failed therapy
with vasoconstrictors could not demonstrate any beneﬁt of
thistherapy,eitheronsystemichemodynamicsoronsurvival
[44].
6.4. Liver Transplantation. Patients with HRS have advanced
liver failure and therefore qualify to undergo liver trans-
plantation. Over all, long-term survival after liver trans-
plantation has been reported to be around 65%. Presence
of HRS, if sepsis is excluded, should be an indication
for urgent/semiurgent liver transplantation. In such cases,
other forms of therapy such as vasoconstrictors or albu-
min dialysis may be used as a bridge to transplantation.
Although recent studies suggest that there is no diﬀerence
in survival between patients with or without HRS (95% 1-
year survival in presence of HRS versus 86% in its absence)
[45], who are transplanted, it is always desirable to have
the renal dysfunction corrected before a patient is taken
up for transplantation. In a retrospective study, 9 patients
with HRS were ﬁrst treated with vasoconstrictors and then
transplanted. These were compared with 27 patients without
HRS who were also transplanted. The outcomes following
transplantation were similar between the two groups with
similar three-year survival probability (100% in treated HRS
group versus 83% in the non-HRS group) [46]. So after
reversal of HRS by vasoconstrictors, the patients should be
listed for a semiurgent liver transplantation even if the serum
creatinine has normalized.
7. Summary
Ascitesandrenalfailureincirrhoticssuggestadvancedportal
hypertension and poor liver function and therefore predict
poor prognosis. Ascites may be the ﬁrst sign of progression
of liver dysfunction or may even suggest an underlying
complication such as development of a hepatocellular car-
cinoma. Mild or moderate ascites can usually be managed
by salt restriction along with diuretics. For severe or tense
ascites, large volume paracentesis with albumin infusion is
requiredalongwithcontinueduseofdiuretics.Forrefractory
ascites, the options are either repeated LVP plus albumin
or TIPS. Renal failure in cirrhotics can be because of a
number of causes, and HRS is not the most common
cause of renal failure among cirrhotics. The most common
cause is either volume responsive prerenal failure or acute
tubular necrosis. Presence of HRS signiﬁes advanced liver
dysfunction, and ideal treatment is liver transplantation for
such patients. But it is advisable to reverse HRS prior to
transplantation. Treatment is initiated by excluding/treating
precipitating causes such as SBP, correction of hypovolemia,
and discontinuation of diuretics. Speciﬁc treatment involves
the use of a combination of vasoconstrictors and albumin.
Terlipressin has been shown to be eﬀective in most cases,
and noradrenaline has also been shown to be as eﬀective
as terlipressin. Another strategy which has been found to
be eﬀective is a combination of midodrine, octreotide,
and albumin. TIPS has also been shown to be eﬀective in
improving renal failure in patients with HRS but should
only be used as a bridge to liver transplantation. Finally,
for both patients with ascites and HRS, the treatment of
choice remains liver transplantation which corrects the basic
pathophysiology of these two complications.
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